- Financial results to be released February 22, 2012 -
Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Feb. 15, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:
DND) will host a conference call on Wednesday, February 22, 2012 at
8:30 a.m. (ET) to discuss its fiscal 2011 financial results. Cipher
invites all interested parties to participate. You can join the call by
dialing 647-427-7450 or 1-888-231-8191. Please call in 15 minutes prior to the call to secure a line. You will
be put on hold until the conference call begins.
Larry Andrews, President and CEO, will chair the call. A question and
answer session will follow, at which time the operator will direct
participants as to the correct procedure for submitting questions. A
taped replay of the conference call will be available until Wednesday,
February 29, 2012 by calling 416-849-0833 or 1-855-859-2056, reference
A live audio webcast of the conference call will be available through www.cipherpharma.com. Please connect at least 15 minutes prior to the conference call to
ensure adequate time for any software download that may be needed to
hear the webcast. An archived replay of the webcast will be available
for 365 days.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals is a growing specialty pharmaceutical company
that commercializes novel formulations of successful, currently
marketed molecules. Cipher's strategy is to in-license clearly
differentiated products, advance them through the clinical development
and regulatory approval stages, and out-license to international
marketing partners. The Company's first product is a fenofibrate
formulation marketed in the United States as Lipofen®. Cipher's second
product, an extended-release tramadol, is marketed in the United States
as ConZip™ and will be marketed in Canada as Durela™. Cipher's New Drug
Application for its third product, a novel formulation of the acne
treatment isotretinoin, is currently being reviewed by the FDA and
Cipher is listed on the Toronto Stock Exchange under the symbol 'DND'
and has approximately 24 million shares outstanding. For more
information, please visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
For further information:
The Equicom Group
(416) 815-0700 ext 278
(416) 815-0080 fax
President and CEO
(905) 602-5840 ext 324
(905) 602-0628 fax